Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
<iframe src="https://statesidedaily.com/embed/cluster/e6fabf9a8aff0d29ea1f8a93e26ec54635e683ff" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'"></iframe>
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
